Serial No.: 09/509,559

Amendments to the claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-29 and 35-37 (canceled)

30. (Previously presented) A purified peptide consisting of sequence ERRGHLRPSFHGHHEKGKEGQVLQRS (OB-CDGF) (SEQ ID NO: 10).

31. (Previously presented) A method comprising administering the peptide according to claim30 to a person in need thereof to promote proliferation of osteoblasts.

32. (Previously presented) A medicament containing the purified peptide according claim 30, together with auxiliary agents.

33. (Previously presented) A medicament containing the purified peptide according claim 30 in a galenic formulation.

34. (Previously presented) The medicament according to claim 32 in a form for administration selected from the group consisting of (a) a galenic formulation, wherein administration is by oral, intravenous, intramuscular, intracutaneous, or intrathecal route, and (b) an aerosol, wherein administration is transpulmonary.

38. (Previously presented) A process for the preparation of the purified peptide according to claim 30 comprising

- isolating the peptide from a hemofiltrate using (i) cation-exchange extraction followed by (ii) elution of adsorbed substances to produce a first extract containing proteins, (iii)

Attorney Docket No. P65315US0

Serial No.: 09/509,559

renewed cation-exchange chromatography of the first extract to produce a second extract containing proteins, and subjecting the second extract to multistage reverse-phase chromatography to produce the purified peptide protein; or

- synthesizing the peptide by solid-phase or liquid-phase synthesis; or
- recombinant, heterologous expression of DNA encoding the peptide.